Bone safety of dual-release hydrocortisone in patients with hypopituitarism

G. Mazziotti, A.M. Formenti, S. Frara, E. Roca, P. Mortini, A. Berruti, A. Giustina, Management of endocrine disease: risk of overtreatment of patients with adrenal insufficiency: current and emerging aspects. Eur. J. Endocrinol. 177, R231–R248 (2017) E. Canalis, G. Mazziotti, A. Giustina, J.P. Bilezikian, Glucocorticoid-induced osteoporosis: pathophysiology and therapy. Osteoporos. Int. 18, 1319–1328 (2007) G. Mazziotti, A.M. Formenti, R.A. Adler, J.P. Bilezikian, A. Grossman, E. Sbardella, S. Minisola, A. Giustina, Glucocorticoid-induced osteoporosis: pathophysiological role of GH/IGF-I and PTH/vitamin D axes, treatment options and guidelines. Endocrine 54, 603–611 (2016) A. Angeli, G. Guglielmi, A. Dovio, G. Capelli, D. de Feo, S. Giannini, R. giorgino, L. Moro, A. Giustina, High prevalence of asymptomatic vertebral fractures in post-menopausal women receiving chronic glucocorticoid therapy: a cross-sectional outpatient study. Bone 39, 253–259 (2006) G. Johannsson, A. Falorni, S. Skrtic, H. Lennernäs, M. Quinckler, J.P. Monson, P.M. Stewart, Adrenal insufficiency: review of clinical oucomes with current glucocorticoid replacement therapy. Clin. Endocrinol. 82, 2–11 (2015) C. Hammarstrand, O. Ragnarsson, T. Hallén, T. Skoglund, A.G. Nilsson, G. Johannsson, D.S. Olsson, Higher glucocorticoid replacement doses are associated with increased mortality in patients with pituitary adenoma. Eur. J. Endocrinol. 177, 251–256 (2017) V. Camozzi, C. Betterle, A.C. Frigo, V. Zaccariotto, M. Zaninotto, E. De Caneva, P. Lucato, W. Gomiero, S. Garelli, C. Sabbadin, M. Salvà, M. Dalla Costa, M. Boscaro, G. Luisetto, Vertebral fractures assessed with dual-energy X-ray absorptiometry in patients with Addison’s disease on glucocorticoid and mineralocorticoid replacement therapy. Endocrine https://doi.org/10.1007/s12020-017-1380-8 (2017) A. Giustina, A.R. Bussi, C. Jacobello, W.B. Wehrenberg, Effects of recombinant human growth hormone (GH) on bone and intermediary metabolism in patients receiving chronic glucocorticoid treatment with suppressed endogenous GH response to GH-releasing horomne. J. Clin. Endocrinol. Metab. 80, 122–129 (1995) G. Mazziotti, T. Porcelli, A. Bianchi, V. Cimino, I. Patelli, C. Mejia, A. Fusco, A. Giampietro, L. De Marinis, A. Giustina, Glucocortioid replacement therapy and vertebral fractures in hypopituitary adult males with GH deficiency. Eur. J. Endocrinol. 163, 15–20 (2010) G. Johannsson, R. Bergthorsdottir, A.G. Nilsson, H. Lennernas, T. Hedner, S. Skrtic, Improving glucocorticoid replacement therapy using a novel modified-release hydrocortisone tablet: a pharmacokinetic study. Eur. J. Endocrinol. 161, 119–130 (2009) G. Johannsson, A.G. Nilsson, R. Bergthorsdottir, P. Burman, P. Dahlgvist, B. Ekman, B.E. Engström, T. Olsson, O. Ragnarsson, M. Ryberg, J. Wahlberg, B.M. Biller, J.P. Monson, P.M. Stewart, H. Lennernäs, S. Skrtic, Improved cortisol exposure-time profile and outcome in patients with adrenal insufficiency: a prospective randomized trial of a novel hydrocortisone dual-release formulation. J. Clin. Endocrinol. Metab. 97, 473–481 (2012) R. Giordano, F. Guaraldi, E. Marinazzo, F. Fumarola, A. Rampino, R. Berardelli, I. Karamouzis, M. Lucchiari, T. Manetta, G. Mengozzi, E. Arvat, E. Ghigo, Improvement of anthropometric and metabolic parameters, and quality of life following treatment with dual-release hydrocortisone in patients with Addison’s disease. Endocrine 51, 360–368 (2016) R.M. Paragliola, S.M. Corsello. Secondary adrenal insufficiency: from the physiopathology to the possible role of modified-release hydrocortisone treatment. Minerva Endocrinol. https://doi.org/10.23736/S0391-1977.17.02701-8 (2017) J.T. Schousboe, J.A. Shepherd, J.P. Bilezikian, S. Baim, Executive summary of the 2013 international society for clinical densitometry position development conference on bone densitometry. J. Clin. Densitom. 16, 455–466 (2013) D.E. Henley, S.L. Lightman, Cardio-metabolic consequences of glucocorticoid replacement: relevance of ultradian signalling. Clin. Endocrinol. 80, 621–628 (2014) S.W. Ing, L.T. Sinnott, S. Donepudi, E.A. Dabies, R.P. Pelletier, N.E. Lane, Change in bone mineral density at one year following glucocorticoid with drawal in kidney transplant recipients. Clin. Transplant. 25, E113–E123 (2011) G. Martí, R. Gómez, E. Jódar, C. Loinaz, E. Moreno, E. Hawkins, Long-term follow-up of bone mass after orthotopic liver transplantation: effect of steroid withdrawal from the immunosuppressive regimen. Osteoporos. Int. 13, 147–150 (2002) G. Mazziotti, A. Bianchi, S. Bonadonna, M. Nuzzo, V. Cimino, A. Fusco, L. De Marinis, A. Giustina, Increased prevalence of radiological spinal deformities in adult patients with GH deficiency: influence of GH replacement therapy. J. Bone Miner. Res. 21, 520–528 (2006) G. Mazziotti, A. Giustina, Glucocorticoids and the regulation of growth hormone secretion. Nat. Rev. Endocrinol. 9, 265–276 (2013) A. Giustina, G. Mazziotti, E. Canalis, Growth hormone, insulin-like growth factors, and the skeleton. Endocr. Rev. 29, 535–559 (2008) A. Giustina, G. Mazziotti, Growth hormone replacement therapy and fracture risk. Lancet Diabetes Endocrinol. 3, 307–308 (2015) M. Quinkler, R.M. Nilsen, K. Zopf, M. Ventz, M. Øksnes, Modified-release hydrocortisone decreases BMI and HbA1c in patients with primary and secondary adrenal insufficiency. Eur. J. Endocrinol. 172, 619–626 (2015)